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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of interventions for treating people with the symptoms of bladder pain syndrome (BPS).
B A C K G R O U N D
Description of the condition
Bladder pain syndrome (BPS), which includes the condition inter-
stitial cystitis, is a chronic conditionmostly affectingwomen and is
characterised by pain in the bladder and/or pelvis andother urinary
symptoms, such as urgency and frequency (Hanno 2017). The
causes of BPS remain poorly understood and no single causative
trigger or validated diagnostic markers have been identified. Thus,
diagnosis primarily relies on reported symptoms and the exclusion
of any other identifiable causes (Hanno 2017).
The National Institute of Diabetes and Digestive and Kidney Dis-
eases (NIDDK) developed stringent diagnostic guidelines for in-
terstitial cystitis based on objective cystoscopic and urodynamic
evaluation (NIDDK 2017). Such evaluation involves putting the
patient under local or general anaesthesia and catheterisation of
the urinary bladder, and so is associated with substantial risks and
costs. The NIDDK criteria have helped inform the selection of
homogeneous patient populations for research purposes but have
proven too strict for use in routine clinical practice (Hanno 1999).
Consequently, the International Continence Society (ICS) pro-
posed a broader term, ’painful bladder syndrome’ (Abrams 2002).
The European Society for Study of Interstitial Cystitis/Bladder
Pain Syndrome (ESSIC) provided a new term, ’bladder pain syn-
drome (BPS)’, defined as “Chronic pelvic pain, pressure or dis-
comfort of greater than sixmonths duration perceived to be related
to the urinary bladder accompanied by at least one other urinary
symptom like persistent urge to void or urinary frequency. Con-
fusable diseases as the cause of the symptoms must be excluded”
(van de Merwe 2008). This definition was accepted by the Inter-
national Consultation of Incontinence in 2010 (Hanno 2010).
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In this Cochrane Review, we will refer to the condition as BPS,
while we will also consider some older literature using the original
terminology.
The lack of a universally accepted clinical diagnosis of BPS makes
epidemiological studies of the condition problematic. Prevalence
estimates vary widely depending on diagnostic criteria and on
how prevalence estimates were derived (i.e. self-report, physician
diagnoses and/or symptom-based surveys). One estimate is that
BPS is experienced by 100 to 200 per 100,000women, with amale
prevalence of 10% to 20% of the estimate for females (Hanno
2017), although it is accepted that BPS is more common than
suggested by empirical studies (Hanno 2017). BPSmay negatively
impact the quality of life and psychological state of people with
the condition, with some experiencing depression, anxiety, distress
and sexual dysfunction (Cox 2016).
Although not consistently present (particularly in non-ulcerative
BPS), the main pathological feature of BPS is inflammation of the
bladder. This leads to vasodilation, enhanced vascular permeability
and degradation of the urothelium’s mucosal glycosaminoglycans
coating. When inflammation is present, it can spread to deeper
tissues of the bladder and, in some cases, Hunner’s lesions may
appear in the bladder wall. This is often referred to as ulcerative
BPS. It is thought this abnormal inflammation of the bladder
underlies the symptoms of pain (Grover 2011; Logadottir 2014).
To date, no definitive consensus has been reached on how or why
BPS develops.
Description of the intervention
Treatment options for BPS are varied (Hanno 2017). Current clin-
ical guidelines emphasise that an individualised treatment plan is
likely to lead to better patient outcomes (Cox 2016). Usually, the
initial treatment of BPS comprises patient education and support,
dietarymanipulation, stress reduction, non-prescription analgesics
and pelvic floor relaxation techniques. When the conservative ap-
proach fails, or symptoms are severe and the conservative man-
agement is unlikely to succeed, pharmacological interventions in-
cluding analgesics, antidepressants, antibiotics and immune mod-
ulators, may be used either orally or intravesically (directly into the
bladder). As a last approach, surgery, including botulinum toxin
A injections or removal of the bladder, may be considered (Hanno
2017).
How the intervention might work
Conservative interventions can be beneficial in reducing the symp-
toms associated with BPS, including dietary and lifestyle changes,
behavioural modifications (e.g. patient education, bladder retrain-
ing) and psychological therapies (e.g. stress management tech-
niques). Women with BPSmay also have pelvic floor dysfunction,
and physical therapy techniques such as pelvic floor muscle train-
ing and soft tissue massage can be effective in helping to relax the
pelvic floor muscles.
Pharmacological treatments address the many theories of patho-
genesis, including the following.
• Analgesics, such as non-steroidal anti-inflammatory drugs
(NSAIDs), target the main symptom of pain.
• Antidepressants are often used to manage pain in chronic
conditions, including BPS.
• Antibiotics are known to decrease the markers of bladder
inflammation, thus reducing pain.
• Immune modulators, such as Bacillus Calmette-Guerin
(BCG), are believed to work immunologically, on the basis of an
autoimmune cause for interstitial cystitis.
• Steroids are known to have an anti-inflammatory effect.
Surgery should only be considered once all other treatments have
failed (Hanno 2017). People should also be informed of all aspects
of surgery and understand the consequences and potential side
effects of these interventions. Surgical interventions can work in
the following ways.
• Botulinum toxin A injections inhibit the release of chemical
transmitters from nerve fibres and the urothelium.
• A total cystectomy (removal of the bladder) can be
performed for extreme cases. This approach also requires
subsequent urinary diversion to expel urine from the body.
There are also some emerging therapies for treating BPS. These
include:
• hyperbaric oxygen, which involves breathing pure oxygen in
a pressurised chamber;
• monoclonal antibodies, which inhibit nerve growth factors
and act as potential analgesics;
• cannabinoids, which could help relieve the symptoms of
BPS; and
• intravesical liposomes, which could potentially protect
against inflammation.
The algorithm for diagnosis and treatment proposed at the sixth
International Consultation on Incontinence in 2016 is presented
in Figure 1 (Hanno 2017).
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Figure 1. Algorithm for diagnosis and treatment: 2016 International Consultation on Incontinence. Taken
from Hanno 2017 and reproduced with permission from Abrams 2017.
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Why it is important to do this review
BPS is a condition with an unknown cause and primarily sub-
jective symptoms. More information is needed about the effects
and safety of available treatment options and therapies. Currently,
there are several small trials assessing a wide range of treatment
options but the number of large trials comparing one treatment
versus another is limited (there is one existing Cochrane Review
on intravesical treatments for BPS (Dawson 2007)). However, a
Cochrane Review increasing coverage to all clinical interventions
by any route of administration, including both direct and indirect
comparisons, will help to provide valuable information to inform
clinical practice.
O B J E C T I V E S
To assess the effects of interventions for treating people with the
symptoms of bladder pain syndrome (BPS).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include parallel group or cross-over randomised controlled
trials (RCTs) or quasi-RCTs (e.g. alternate allocation) of interven-
tions for treating BPS.
Types of participants
Allowing for the many terminologies that have been used for the
condition, we will include trials where adults are specified as hav-
ing BPS, interstitial cystitis or painful bladder syndrome. We will
accept the classification of diagnoses as defined by the trial investi-
gators and a clinical diagnosis of BPS with or without meeting the
NIDDK criteria will be eligible (NIDDK 2017). We will exclude
studies of adults with urethral syndrome.
Types of interventions
We will include trials of any intervention that aim to cure or im-
prove symptoms of BPS, covering both emerging and more tradi-
tional modes of treatments. All types of interventions are eligible,
including conservative, pharmacological and surgical therapies.
Conservative therapies include behavioural therapies (e.g. bladder
training), psychological therapies (e.g. stress management tech-
niques), complementary therapies (e.g. acupuncture) and physical
therapy (e.g. pelvic floor muscle training and non-invasive elec-
trical stimulation). We will consider pharmacological treatments
regardless of their routes of administration (which are likely to be
oral, subcutaneous, intramuscular, intravenous or intravesical).
Valid comparators are placebo, no treatment or another interven-
tion.
We will exclude trials:
• comparing two or more regimens of the same treatment
(e.g. varying doses of pentosan polysulfate); and
• comparing two or more treatments with the same
mechanism or mode of action (e.g. sacral nerve stimulations
versus pudendal nerve stimulations, both of which are
neuromodulation).
Types of outcome measures
We will use the following definitions of outcomes. If a particular
outcome is reported using different definitions across different
studies then, depending on the amount of data available, we will
decide either to restrict inclusion to the primary (ormost common)
definition or to include multiple definitions selected according to
the hierarchies proposed below. In the event where a study reports
any other measure not included in our proposed list, we will add
this at the bottom of the hierarchy and extract the data.
Primary outcomes
• Number of participants whose symptoms were cured or
improved: self-reported measures are preferred, such as the
Global Response Assessment. We will use objective measures (e.g.
number of participants who experienced pain score reduction) as
a proxy if self-reported measures are unavailable. We will use the
number cured if this is reported. If cure is not reported, we will
use the number improved, as defined by the trial investigators.
• Pain score: we will use the following hierarchy to select one
outcome measure per study: visual analogue scale (VAS);
numerical rating scale (NRS); McGill pain questionnaire
(Melzack 1975; Melzack 1987); SF-36/RAND-36 (if a score for
the pain-specific item is available) (Hays 1993; McHorney 1993;
Ware 1992); and the number of participants with pain reduction.
• Daytime frequency (number of voids): we consider the
following terms to be equivalent to daytime frequency:
frequency; daily frequency; frequency per day; and daytime
frequency. We will exclude 24-hour frequency.
• Nocturia.
Secondary outcomes
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• Subjective symptom measures (combining frequency,
nocturia and pain): we will use the following hierarchy to select
one outcome measure per study: O’Leary-Sant Interstitial
Cystitis Symptom Index (ICSI) (O’Leary 1997); Pelvic Pain and
Urgency/Frequency questionnaire (PUF) (Parsons 2002);
University of Wisconsin Interstitial Cystitis Scale (UW-IC Scale)
(Goin 1998); and King’s Health Questionnaire (KHQ), Part III
(Kelleher 1997).
• Quality of life (including symptom bother): we will use the
following hierarchy to select one outcome measure per study:
O’Leary-Sant Interstitial Cystitis Problem Index (ICPI) (O’Leary
1997); Pelvic Pain and Urgency/Frequency questionnaire (PUF),
Bother score (Parsons 2002); King’s Health Questionnaire
(KHQ) (Kelleher 1997); SF-36 and SF-12, Mental component
(McHorney 1993; Ware 1992; Ware 1996); and SF-36 and SF-
12, Physical component (McHorney 1993; Ware 1992; Ware
1996).
• Functional bladder capacity: this is defined using the
following terms for the purpose of the review: functional bladder
capacity; functional bladder volume; bladder capacity; maximum
bladder capacity; and maximum tolerable bladder capacity. We
will exclude volume at first or strong desire to void, (mean)
voided volume, (maximum) cystometric bladder capacity, or
urodynamic capacity.
• Adverse events: the category of adverse events will be
accepted as reported by the study authors.
Timing of outcome assessment
The primary time point for outcome assessment is at 12months or
the nearest time point available to 12 months. For all continuous
outcomes (e.g. pain scores), we will use observed final scores post-
intervention if reported, with the change score from the baseline
used as a proxy.
Main outcomes for ’Summary of findings’ tables
• Number of participants whose symptoms were cured or
improved
• Pain score
• Daytime frequency
• Nocturia
Search methods for identification of studies
We will not impose any language or other limitations on any of
the searches described below.
Electronic searches
We will perform searches drawing on the search strategy devel-
oped for Cochrane Incontinence. We will identify relevant trials
from the Cochrane Incontinence Specialised Register. For more
details of the search methods used to build the Specialised Regis-
ter, please see the Group’s webpages where details of the Register’s
development (from inception) and the most recent searches per-
formed to populate the Register can be found. To summarise, the
Register contains trials identified from the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, MEDLINE
In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov,
WHO ICTRP, the UK Clinical Research Network Portfolio and
handsearching of journals and conference proceedings. Many of
the trials in the Cochrane Incontinence Specialised Register are
also contained in CENTRAL.
The terms that will be used to search the Cochrane Incontinence
Specialised Register are given in Appendix 1.
Searching other resources
We will identify relevant studies from an existing Cochrane Re-
view on intravesical treatments for BPS (Dawson 2007). We will
also screen the reference lists from the included studies for other
relevant trials.
Data collection and analysis
Selection of studies
One review author (SW) will establish the selection of studies
from the relevant Cochrane Review on intravesical treatments for
BPS (Dawson 2007), which a second review author (MI) will
check. Two review authors (JO and AF) will independently screen
the titles and abstracts of all citations identified by the literature
searches. The same two review authors will evaluate full-text copies
of all potentially relevant reports. We will resolve any discrepancy
or inconsistency by recourse to a third review author (SW,MI, NS
or MB).
We will obtain translations of eligible studies where resources al-
low, including any available translated information obtained by
Dawson 2007. If translations are not obtained, we will add these
studies to ’Studies awaiting classification’ and discuss the implica-
tions of any missing information in the ’Overall completeness and
applicability of the evidence’ section of the completed review.
Data extraction and management
We will export study characteristics and outcome data of individ-
ual studies from the relevant Cochrane Review (Dawson 2007),
and one review author (MI or YAD) will check them against indi-
vidual trial reports. From additional studies identified by updated
literature searches, one review author (MI or YAD) will perform
data extraction using a prepiloted data form, which another review
author (MI or YAD) will check. We will resolve any discrepancy
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or inconsistency by recourse to a third review author (SW, NS or
MB).
We will collect information on study design and setting, partici-
pant characteristics (including disease diagnosis), study eligibility
criteria, details of the intervention(s) given, the outcomes assessed
and the source of study funding for each included study. We will
map multiple publications of a primary study to unique studies
and we will extract the most complete data across all known pub-
lications.
For binary outcomes, we will extract the total number of partici-
pants in each treatment arm and the number with the event. For
continuous outcomes, wewill extractmean scores (i.e. mean scores
at follow-up or mean change scores from baseline) in each arm
along with standard deviation (SD) and the number of partici-
pants. If both final scores and change scores are available, we will
use final scores in the analysis.
Assessment of risk of bias in included studies
We will use the original risk of bias assessments made by the re-
view authors of the relevant Cochrane Review (Dawson 2007).
Judgements were made for the following criteria.
• Adequacy of randomisation, description of allocated groups
prior to treatment and blinding to allocation.
• Adherence to prescribed treatment once allocated.
• Adequacy of follow-up and accounting for participants
excluded/withdrawing from trial.
• Analysis of participants based on allocated treatment group
and adequacy of presented data.
Two review authors working independently (JO and AF) will up-
date assessments using Cochrane’s ’Risk of bias’ assessment tool
(Higgins 2011a).We will resolve any discrepancy or inconsistency
by recourse to a third review author (SW, NS or MB). The new
assessments will address the following domains.
• Random sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessor (detection bias)
• Incomplete outcome data (attrition bias)
• Free of selective reporting (reporting bias)
• Other sources of bias
We will judge each included study to be at ‘low’, ’high’ or ’unclear’
risk of bias.
Measures of treatment effect
For binary outcomes, we will use odds ratios (ORs) as themeasure
of treatment effect. For continuous outcomes, we will use the
difference in means.
Unit of analysis issues
We will only include patient randomised trials in this review and
the unit of analysis will be individual participants.
For cross-over trials, we will use data from paired analyses when
available. In cross-over studies where paired analyses are not re-
ported, we will use data from the first trial period if these are pre-
sented separately, as detailed in the Cochrane Handbook for System-
atic Reviews of Interventions, section 16.4.5 (Higgins 2011b). We
will exclude cross-over studies from the analysis if only data for
the first and second periods combined are available.
If two or more arms of a multi-arm trial belong to the same treat-
ment category, we will combine data using standard pooling for-
mulae (Higgins 2011b).
Dealing with missing data
We will employ a number of approaches to calculate or estimate
SDs when these were not reported, though the standard methods
described in the Cochrane Handbook for Systematic Reviews of In-
terventions will be preferred (Higgins 2011c). If standard errors
(SEs) are reported, we may derive the SD using the appropriate
standard formula, as detailed in the Cochrane Handbook for Sys-
tematic Reviews of Interventions, section 7.7.3.2 (Higgins 2011b).
If necessary, we will calculate SDs from a 90% or 95% confidence
interval (CI) for a mean difference, from the P value from a t-test
(Higgins 2011b), or imputed using an average from other studies.
Assessment of heterogeneity
For pairwise meta-analyses, we will assess the presence of statis-
tical heterogeneity by visual inspection of the forest plots and by
calculating the I² statistic (Higgins 2003). For networkmeta-anal-
yses, we will investigate consistency between direct and indirect
evidence as outlined in the Data synthesis section below.
Assessment of reporting biases
If there are more than 10 trials per comparison in each outcome,
we will examine funnel plots to assess reporting bias.
Data synthesis
We will divide interventions into treatment categories, classified
as conservative, pharmacological or surgical interventions. The
total number of treatment categories that could be included in
each analysis will depend on the number of studies that provide
useable data for the outcomes of interest. If considered clinically
appropriate (e.g. if treatment B is considered a routine therapy), we
will ’cancel’ treatments (e.g. a trial of A + B versus B will become A
versus control). If this is not appropriate, wewill use a combination
of therapies as a single treatment category (e.g. chondroitin sulfate
plus hyaluronic acid).We will combine different doses of the same
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treatment as a single category, provided this is considered clinically
appropriate.
We will perform two approaches to meta-analysis. The primary
method will be network meta-analysis but we will also conduct
standard pairwise meta-analyses and compare the results with
those from the network meta-analysis.
Network meta-analysis
We will follow the recommendations in the National Institute for
Health andCare ExcellenceDecision SupportUnit Technical Sup-
port Documents 2 (NICE DSU TSD 2) (Dias 2016). Network
meta-analyses models will be fitted using WinBUGS 1.4 and used
to conduct data synthesis of trials (Lunn 2000). We will use a bi-
nomial likelihood for binary outcomes and the normal likelihood
for continuous outcomes. We will use random-effects models due
to the expected heterogeneity between treatments and outcome
measures. Three chains will be used and parameters fitted using
vague normal prior distributions.
For binary outcomes, we will use Program 1(c) from the NICE
DSU TSD 2 (Dias 2016). We will monitor ORs for all treat-
ments in the network against control and present results using
95% credible intervals. ORs greater than one will be associated
with a favourable effect of treatment versus control. We will only
monitor the effect of active treatments versus control.
For continuous outcomes, the effect size will be the mean differ-
ence between groups but we will onlymonitor differences between
active treatments and control. For each outcome, high scores will
represent poorer outcomes than lower scores. Therefore, effect sizes
of less than zero will mean that the treatment group is favoured.
We will use a shared parameter model (Program 8(a) from the
NICE DSU TSD 2) in order to simultaneously incorporate two
data formats (Dias 2016):
• final score arm-based data; and
• contrast-based differences in change from baseline.
For the network meta-analysis, there is an additional assumption
of transitivity, i.e. that included participants should be eligible to
be randomised to any treatment within the network. Violations
of this assumption can be investigated by examining the consis-
tency between direct and indirect evidence. We intend to use the
methods described in the NICE DSU TSD 4 to compare closed
loops within the network (Dias 2014).
We will produce network diagrams for each outcome using the
networkplot command in Stata (Stata 2017). Lines between treat-
ment categories mean that direct evidence exists between a pair of
treatments. The thickness of the line is proportional to the num-
ber of included studies.
Pairwise meta-analyses
We will compare the results of the network meta-analysis with the
direct evidence from head-to-head trials. For each outcome, we
will perform a separate pairwise meta-analysis for each treatment
category versus control. Meta-analyses will be conducted using the
metan command in Stata (Stata 2017).We will not conduct meta-
analyses between each pair of active treatments. The number of
trials contributing to the pairwise meta-analyses may be smaller
than those included in the network meta-analysis because only
trials with a control group will be included.
For binary outcomes, we will pool ORs for each treatment versus
control. We will use the Mantel-Haenszel approach to meta-anal-
ysis using random-effects models in Stata as the primary analysis
(Stata 2017). For continuous outcomes, the effect size will be the
mean difference between treatment and control.Wewill use amix-
ture of change score and final score data within the same analysis
(see the Cochrane Handbook for Systematic Reviews of Interventions,
section 9.4.5.2; Deeks 2011). We will combine studies using the
inverse variance weighted approach and present results using 95%
confidence intervals (CIs).
Subgroup analysis and investigation of heterogeneity
We do not plan to conduct subgroup analyses.
Sensitivity analysis
We do not plan to conduct sensitivity analyses.
GRADE and ’Summary of findings’ tables
We will prepare ’Summary of findings’ tables for the main com-
parisons.
We will assess the overall quality of evidence for each of the out-
comes listed in the ’Main outcomes for ’Summary of findings’
table’ using the GRADE approach (Guyatt 2008; Guyatt 2011;
Schünemann 2011). We will rate each outcome as ‘high’, ‘moder-
ate’, ‘low’, or ‘very low’, taking into account five criteria: study lim-
itations, inconsistency, imprecision, indirectness and publication
bias. We will apply the GRADE approach modified for network
meta-analysis (Salanti 2014), and plan to explore the use of the
CINeMA 2017 web application in order to implement this ap-
proach. If this application is not suitable for the purposes of this re-
view, we will use Microsoft Excel 2016 instead. We will follow the
guidance in the latest draft version of the Cochrane Handbook for
Systematic Reviews of Interventions chapter on network meta-anal-
ysis to develop our own ’Summary of findings’ tables (Chaimani
2017).
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A P P E N D I C E S
Appendix 1. Cochrane Incontinence Specialised Register - search terms
We will search the Cochrane Incontinence Specialised Register using the following search terms:
DESIGN.CCT* or DESIGN.RCT*
AND
TOPIC.URINE.INTERSTITIAL CYSTITIS.
All searches are of the ’Keyword’ field in EndNote 2018.
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